Our research aims to develop diagnostic and therapeutic tools for cancer fighting by studying the vectorization of radionuclides to cancer cells and their biological effects.
Our research program is structured around three main areas:
Axis 1: Targeted radiotherapy
The main objective of this strategy is to eradicate cancer cells using various radiolabelled vectors such as antibodies and their fragments, peptides, Affitins and liposomes. For instance, the efficacy of radioimmunotherapy (RIT) has been demonstrated in the treatment of certain lymphomas for which it is integrated into the therapeutic arsenal. Nantes’ nuclear medicine department is at the forefront of this development in France and is pursuing its lymphoma research activity by targeting new antigens or applying two-steps RIT to the treatment of small cell lung cancer.
The Nuclear Oncology team is one of the few French teams to develop the use of alpha emitters in this targeting approach.
Axis 2: Molecular imaging
The second objective is to develop molecular imaging, particularly positron emission tomography (PET) of cancers. This last way provides crucial information for improving the therapeutic management of cancer: disease staging, proliferative capacity, prognosis, objectification of the effect of a treatment, therapeutic follow-up, etc. The latter is crucial for improving the therapeutic management of cancer.
Targeted radiotherapy and molecular imaging use similar techniques; radionuclides (adapted to each goal), vectors, radiolabelling, medical physics. They also agree that targeted radiotherapy needs molecular imaging: expression of the target antigen, effectiveness of targeting, quantitative imaging for dosimetry.
Axis 3: Radiobiology
Our team develops the use of alpha particle emitters in therapy. We also combine this molecular radiotherapy with other approaches. Indeed, it is now clearly established that the action of ionizing radiation is not limited to direct cytotoxicity on tumour cells but that these radiation are able, in particular, to elicit an immune response. With this in mind, we are working on studying the biological effects of alpha ionizing radiation on tumour tissues.
Our project aims to combine these approaches to propose innovations and drive them, over the years, from the laboratory to the clinic.
This transfer involves translational research using animal models carrying induced (mouse) or spontaneous (dog) tumours to answer questions arising in the clinical practice of vectorized radiotherapy and molecular imaging.
Our multidisciplinary team develops a broad expertise in chemistry, radiochemistry, radiobiology, immunology, medical physics, protein engineering and preclinical imaging (Applied Multimodal Imaging Centre – CIMA) to support nuclear medicine.
- June 2018: François Davodeau has received a grant from ARC
- May 2018 : Timothée Hernandez (Master 1, Chemistry) and Jennifer Jazat (AI CDD Inserm) have joined us
- March 2018:
- Job offer (closed)
- Liyan Ouyang (Master 2, Chemistry) has joined us
- February 2018: Hermelyne Gravouelle (AI CDD Inserm) and Aurélie Loussouarn (Master 2, BMTI) have joined us
- François Davodeau, CR Inserm
- Jean François Gestin, DR Inserm
- François Guérard CR CNRS
- Frédéric Pecorari, CR CNRS
- Axelle Renodon-Cornière, CR CNRS
- Caroline Bodet-Milin, MCU-PH
- Mickaël Bourgeois, MCU-PH
- Nicolas Chouin, MCU Oniris
- Alain Faivre-Chauvet, PU-PH
- Joëlle Gaschet, MCU Univ. Nantes
- Yannick Guilloux, PU Univ. Nantes
- Catherine Ibisch, MCU Oniris
- Marie Mougin-Degraef, MCU-PH
- Barbara Mouratou, MCU Univ. Nantes
- Latifa Rbah-Vidal, MCU Univ. Nantes
- Caroline Rousseau, MCU-PH ICO
Engineers & technicians
- Cyrille Alliot, IR Inserm Arronax
- Ghislaine Béhar, IE CNRS
- Valérie Bossé, AI Inserm
- Catherine Chauvet TR Univ. Nantes
- Marie-Hélène Gaugler, IR CDI Univ. Nantes – LabEx IRON
- Sébastien Gouard, IE CDI Univ. Nantes
- Hermelyne Gravouelle, AI CDD Inserm
- Françoise Léost, IR CDI CHU-CGO
- Catherine Maurel, IE Inserm
- Patricia Remaud-Le Saec, IE Univ. Nantes
- Clément Bailly
- Marion Berdal
- Benjamin Chalopin
- Marisa Fernandes Capitao
- Aurélie Loussouarn
- Maël Millardet
- Floriane Morio
- Ludivine Morvan
- Anne-Sophie Navarro
- Justine Perrin
- Zainab Tabaja
- Petar Vukojicic
- Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma
Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-Bodere F, Carlier T, Bodet-Milin C.
PLoS One. 2017 Aug 25;12(8):e0183841
- Radioimmunoconjugates for treating cancer: recent advances and current opportunities
Bourgeois M, Bailly C, Frindel M, Guerard F, Chérel M, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C.
Expert Opin Biol Ther. 2017 Jul;17(7):813-819
- PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C.
Int J Mol Sci. 2017 Feb 18;18(2). pii: E445
- ImmunoPET to help stratify patients for targeted therapies and to improve drug development
Kraeber-Bodere F, Bailly C, Chérel M, Chatal JF.
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2166-2168
Our team is a member or leader of:
- Doctoral school membership: Biologie-Santé
- Associated masters: M1 Sciences et santé, M1 Sciences biologiques, M2 BBRT et M2 SBIM
- Mooc “Au cœur de la radioactivité médicale”